Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
GlaxoSmithKline ( (GSK) ) has provided an announcement.
On 16 March 2026, GSK repurchased 628,000 ordinary shares of 31.25 pence each through BNP Paribas at prices between 2,026p and 2,052p, with a volume-weighted average price of 2,035.82p, as part of its ongoing share buyback programme. The shares will be held in treasury, taking total treasury holdings to 250,444,503 shares, leaving 4,065,726,262 shares in issue and establishing total voting rights at the same figure, with 6.16% of voting rights now attributable to treasury shares under UK disclosure rules.
The latest transaction brings GSK’s cumulative purchases since 17 February 2026 to 10,553,409 ordinary shares, underscoring the company’s continued capital-return strategy and active balance-sheet management. By increasing treasury holdings and confirming the updated denominator for voting-right calculations, the buyback affects institutional and retail investors’ disclosure thresholds and slightly concentrates ownership among remaining free-float shareholders while signalling management’s confidence in the company’s valuation.
The most recent analyst rating on (GSK) stock is a Hold with a $58.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GSK Stock Forecast page.
Spark’s Take on GSK Stock
According to Spark, TipRanks’ AI Analyst, GSK is a Neutral.
The score is supported primarily by resilient fundamentals (strong profitability and positive cash generation) and a constructive earnings outlook with higher dividend guidance and continued specialty/HIV momentum. These positives are tempered by leverage and recent revenue/FCF volatility, while technically the stock is in a strong uptrend but looks overbought, raising near-term pullback risk.
To see Spark’s full report on GSK stock, click here.
More about GlaxoSmithKline
GSK plc is a global biopharmaceutical company headquartered in London, focused on developing, manufacturing and commercializing prescription medicines and vaccines. The group targets major therapeutic areas such as infectious diseases, HIV, respiratory and oncology, and is a constituent of the UK large-cap equity market with shares listed on the London Stock Exchange.
Average Trading Volume: 5,256,325
Technical Sentiment Signal: Buy
Current Market Cap: $107.9B
For a thorough assessment of GSK stock, go to TipRanks’ Stock Analysis page.